Product Information PI - Roche Australia
Product Information PI - Roche Australia
Product Information PI - Roche Australia
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
TAMIFLU and placebo arm was < 1%, were the following:<br />
Gastrointestinal Disorders (TAMIFLU versus placebo)<br />
- Treatment: diarrhoea (6% vs. 7%), abdominal pain (incl. upper abdominal pain, 2%<br />
vs. 3%)<br />
- Prophylaxis: diarrhoea (3% vs. 4%), upper abdominal pain (2% vs. 2%), dyspepsia<br />
(1% vs. 1%)<br />
Infections and Infestations (TAMIFLU vs. placebo)<br />
- Treatment: bronchitis (3% vs. 4%), sinusitis (1% vs. 1%), herpes simplex (1% vs.<br />
1%)<br />
- Prophylaxis: nasopharyngitis (4% vs. 4%), upper respiratory tract infections (3% vs.<br />
3%), influenza (2% vs. 3%)<br />
General Disorders (TAMIFLU vs. placebo)<br />
- Treatment: dizziness (incl. vertigo, 2% vs. 3%),<br />
- Prophylaxis: fatigue (7% vs. 7%), pyrexia (2% vs. 2%), influenza like illness (1%<br />
vs. 2%), dizziness (1% vs. 1%), pain in limb (1% vs.